On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.

doi:10.1186/s12943-021-01479-4

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.

Molecular cancer - 3 Jan 2022

Jiang Tao, Chen Jianhua, Xu Xingxiang, Cheng Ying, Chen Gongyan, Pan Yueyin, Fang Yong, Wang Qiming, Huang Yunchao, Yao Wenxiu, Wang Rui, Li Xingya, Zhang Wei, Zhang Yanjun, Hu Sheng, Guo Renhua, Shi Jianhua, Wang Zhiwu, Cao Peiguo, Wang Donglin, Fang Jian, Luo Hui, Geng Yi, Xing Chunyan, Lv Dongqing, Zhang Yiping, Yu Junyan, Cang Shundong, Zhang Yaxi, Zhang Jiao, Yang Zeyu, Shi Wei, Zou Jianjun, Zhou Caicun, Ren Shengxiang

Abstract excerpt

BACKGROUND: Camrelizumab plus chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to chemotherapy alone as first-line treatment in advanced lung squamous cell carcinoma (LUSC) in the phase III trial (CameL-sq), which has become an option of standard-of-cares for Chinese patients with advanced LUSC. However, the predictive biomarkers remain unknown. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carcinoma, Squamous Cell

Share to Cell-Free Nucleic Acids

Share to Combined Modality Therapy

Share to DNA, Neoplasm

Share to Molecular Targeted Therapy

Share to Neoplasm Staging

Source

Open in PubMed Open full text

Identifiers

PMID: 34980131
DOI: 10.1186/s12943-021-01479-4
PMCID: PMC8722280

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.PMID 34980131Read ↗

The landscape of tumor mutational burden and its clinical significance in patients with lung cancer: a Multi-omics study with a meta-analysisSemantic proximity Read ↗

Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute StudySemantic proximity Read ↗

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.Semantic proximity Read ↗

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.Semantic proximity Read ↗

Tumor mutational burden and efficacy of chemotherapy in lung cancer.Semantic proximity Read ↗

The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data baseSemantic proximity Read ↗

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung CancerSemantic proximity Read ↗

Development and validation of a blood-based genomic mutation signature to predict the clinical outcomes of atezolizumab therapy in NSCLC.Semantic proximity Read ↗

Higher Blood-to-Tissue Tumor Mutational Burden Ratio Is Associated With Poorer Overall Survival in Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer.Semantic proximity Read ↗

Cerebrospinal Fluid Circulating Tumor DNA Genotyping and Survival Analysis in Lung Adenocarcinoma With Leptomeningeal MetastasesSemantic proximity Read ↗

Exploring real-world concordance of tissue mutation burden (TMB) from blood and tissue in patients with solid tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.